alexa Development Of A Generic Drug With Different Pharmaceutical Features: A Study Of The Therapeutic Equivalence Of Mometasone Nasal Spray In Patients With Seasonal Allergic Rhinitis (Japanese Cedar Pollinosis) | 72974
ISSN: 2155-9627

Journal of Clinical Research & Bioethics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Advanced Clinical Research and Clinical Trials
September 20-21, 2017 Dublin, Ireland

Minoru Gotoh, Kumi Sugita, Akihiro Saito, Takayuki Honda, Koichiro Hoashi and Takashi Miyazaki
Nippon Medical School, Japan
Ujigawa Hospital, Japan
Taiho Pharmaceutical Co, Japan
Toko Yakuhin Kogyo Co. Ltd., Japan
Posters & Accepted Abstracts: J Clin Res Bioeth
DOI: 10.4172/2155-9627-C1-003
Abstract
TAC-203 is under development as a generic drug for mometasone furoate, and it has pharmaceutical features different from those of original mometasone (OM): As a gel with a different viscosity is used, dripping after spraying and/or pouring the drug solution into the throat is greatly reduced. After the upper exhaust pressure airless spray container is adopted, there is no longer a difference in spraying performance due to differences in the angle of the container. As it is a homogeneous suspension, shaking before use has become unnecessary. No clinical studies in humans have been conducted so far for the development of generic steroid nasal sprays in Japan. However, since this drug has different pharmaceutical features from those of OM, we evaluated the efficacy and safety of the drug by conducting a high-quality therapeutic equivalence study in patients with seasonal allergic rhinitis. We conducted a randomized, evaluator-blinded, active and placebo-controlled study. Patients were randomly (2:2:1) assigned to receive TAC-203 (mometasone 200 μg/day), OM 200 μg/day, or placebo once daily for 2 weeks. The primary efficacy endpoint was the change from baseline in total nasal symptom score (TNSS) at 2 weeks. In addition, blood sample was collected at 1 hour after first administration for evaluating plasma mometasone concentration. 180 patients enrolled (TAC-203: 72, OM: 72, placebo: 36 patients, respectively). 95% confidence interval (-0.427 to 1.112) for the difference between treatments TAC-203-OM in the change from baseline in TNSS at 2 weeks was within the preplanned range of equivalence (-1.13 to 1.13). The geometric mean of mometasone furoate concentration in plasma was 8.85 pg/mL in TAC-203 and 4.87 pg/mL in OM. The therapeutic equivalence of TAC-203 and OM was confirmed by this study. Furthermore, TAC-203 has similar tolerability and safety profiles as OM.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]icsonline.com

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version